Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8801734 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL8973501 | 0.86 | ALDH1A1 (0.47) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL3053745 | 0.81 | PKM (0.67) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL9710339 | 0.80 | CA12 (0.52) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL13469238 | 0.80 | PKM (0.50) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL5078857 | 0.80 | TSHR (0.55) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL102285 | 0.79 | KMT2A (0.54) | ALDH1A1MAPTNPC1KMT2AMEN1 | |
| SCHEMBL14043705 | 0.79 | NPC1 (0.52) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL20598702 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTNPC1RAB9AKMT2A | |
| SCHEMBL6552892 | 0.79 | MAPT (0.55) | ALDH1A1MAPTNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431345-A | Compound for regulating 15-PGDH activity and preparation method thereof | 赛诺哈勃药业（成都）有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-117126176-A | Thienopyrimidine compound and dopamine D thereof 2 Use of receptor allosteric antagonists | 常州大学 | 2023-11-28 | — | — | CN | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3380476-B1 | FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2020-09-30 | — | — | EP | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10556890-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10189825-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180118727-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-0805812-B1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5792767-A | TREATMENT OF BENIGN PROSTATIC HYPERTROPY | ABBOTT LABORATORIES (US) | 1998-08-11 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5521181-A | Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists | ABBOTT LABORATORIES (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0207358-A2 | Growth-promoting agent | BAYER AG (DE) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | ALDH1A1 3410/4885MAPT 4560/4885NPC1 3986/4885 |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | ALDH1A1 1165/4885MAPT 185/4885NPC1 160/4885 |
| US-10556890-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | ALDH1A1 1165/4885MAPT 185/4885NPC1 160/4885 |
| US-20180118727-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | ALDH1A1 1165/4885MAPT 185/4885NPC1 160/4885 |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | ALDH1A1 1165/4885MAPT 185/4885NPC1 160/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | ALDH1A1 4173/4885MAPT 2998/4885NPC1 3385/4885 |
| US-10189825-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | ALDH1A1 1165/4885MAPT 185/4885NPC1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.